BURLINGTON, Mass., Sept. 25, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the colorectal cancer (CRC) market in Turkey will grow at an annual rate of four percent, reaching $90 million in 2017. The Emerging Markets report entitled Colorectal Cancer in Turkey finds that the rapidly growing CRC patient population, the launches of several new branded therapies, and the continued use of branded agents, in particular targeted therapies, Roche's Avastin (Altuzan in Turkey) and Merck's Erbitux, will drive growth in this market.
Between 2012 and 2017, five branded CRC therapies will launch in Turkey, namely Amgen's Vectibix (launched in Turkey in May 2013), Bayer's Stivarga, Sanofi's Zaltrap, Alchemia's HA-irinotecan and Eli Lilly's ramucirumab. As a result of current therapies being well entrenched in the market, new therapies will provide some competition to the existing agents but will not substantially diminish their patient shares—new therapies will together contribute 11 percent to the total CRC market in 2017.
The report also finds that the number of incident cases of CRC in Turkey will almost double between 2012 and 2022, mainly due to an increase in disease risk, but also because of growing and aging population.
"Turkish oncologists frequently use targeted therapies when treating their metastatic CRC patients and interviewed experts report that all of their metastatic patients undergo KRAS testing–this is more in line with the medical practice of the major markets than of some other emerging markets that we cover," said Decision Resources Analyst Natalia Reoutova, MA, MSc. "Although the drug price cuts implemented by the Turkish government have an obvious constraining effect on the market equally, they also allow the targeted agents to enjoy the comparatively high patient shares, which otherwise would be a lot lower."
The new report features extensive primary research with Turkish oncologists as well as a market outlook through 2017.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
|SOURCE Decision Resources|
Copyright©2012 PR Newswire.
All rights reserved